Massive Bio CEO Touts AI Strategy at NYSE
What happened
Selin Kurnaz, CEO of Massive Bio, discussed the company's use of AI in healthcare and clinical trials in a segment hosted by the NYSE. The discussion focused on how AI can improve patient access and enable scaling of operations. This serves as an example of a CEO using capital market platforms to communicate a company's technology and AI narrative directly to the investment community.
Why it matters
- Co-founder and CEO Selin Kurnaz has a background in both engineering and finance, holding five engineering degrees including a Ph.D. from the University of Michigan and having helped establish EY's Private Equity Value Creation team for healthcare investments. - The company's core AI platform, SYNERGY-AI, uses natural language processing to analyze unstructured medical records and match patients to a database of over 19,000 oncology trials. This is augmented by physician-facing tools like "Dr. Arturo AI" and patient-facing tools like "Ask Fiona AI". - Massive Bio is a Series B company that has raised a total of $15.6 million over four funding rounds, with its most recent being a $9 million round in June 2022 led by Revo Capital. - The company's business model serves pharmaceutical firms and contract research organizations (CROs) by accelerating patient recruitment, a major bottleneck in drug development. - Kurnaz was motivated to start the company in 2014 after a family member's experience with cancer, with the stated mission of using technology to overcome geographical and financial barriers to clinical trial access. - In late 2025, the company announced its next-generation platform, Reticulum Nexus, an AI-driven multi-agent system designed to orchestrate the entire patient journey from initial contact to enrollment. - The platform has onboarded more than 160,000 cancer patients and the company operates in 12 countries, partnering with pharmaceutical companies to enable population-based recruitment rather than traditional site-specific methods.
Key numbers
- The company's core AI platform, SYNERGY-AI, uses natural language processing to analyze unstructured medical records and match patients to a database of over 19,000 oncology trials.
- Massive Bio is a Series B company that has raised a total of $15.6 million over four funding rounds, with its most recent being a $9 million round in June 2022 led by Revo Capital.
- Kurnaz was motivated to start the company in 2014 after a family member's experience with cancer, with the stated mission of using technology to overcome geographical and financial barriers to clinical trial access.
- In late 2025, the company announced its next-generation platform, Reticulum Nexus, an AI-driven multi-agent system designed to orchestrate the entire patient journey from initial contact to enrollment.
What happens next
- In late 2025, the company announced its next-generation platform, Reticulum Nexus, an AI-driven multi-agent system designed to orchestrate the entire patient journey from initial contact to enrollment.
Quick answers
What happened in Massive Bio CEO Touts AI Strategy at NYSE?
Selin Kurnaz, CEO of Massive Bio, discussed the company's use of AI in healthcare and clinical trials in a segment hosted by the NYSE. The discussion focused on how AI can improve patient access and enable scaling of operations. This serves as an example of a CEO using capital market platforms to communicate a company's technology and AI narrative directly to the investment community.
Why does Massive Bio CEO Touts AI Strategy at NYSE matter?
Co-founder and CEO Selin Kurnaz has a background in both engineering and finance, holding five engineering degrees including a Ph.D. from the University of Michigan and having helped establish EY's Private Equity Value Creation team for healthcare investments. The company's core AI platform, SYNERGY-AI, uses natural language processing to analyze unstructured medical records and match patients to a database of over 19,000 oncology trials. This is augmented by physician-facing tools like "Dr. Arturo AI" and patient-facing tools like "Ask Fiona AI". Massive Bio is a Series B company that has raised a total of $15.6 million over four funding rounds, with its most recent being a $9 million round in June 2022 led by Revo Capital. The company's business model serves pharmaceutical firms and contract research organizations (CROs) by accelerating patient recruitment, a major bottleneck in drug development. Kurnaz was motivated to start the company in 2014 after a family member's experience with cancer, with the stated mission of using technology to overcome geographical and financial barriers to clinical trial access. In late 2025, the company announced its next-generation platform, Reticulum Nexus, an AI-driven multi-agent system designed to orchestrate the entire patient journey from initial contact to enrollment. The platform has onboarded more than 160,000 cancer patients and the company operates in 12 countries, partnering with pharmaceutical companies to enable population-based recruitment rather than traditional site-specific methods.
